SK Hynix Joins $1 Trillion Club as AI Chip Demand Fuels Stock Surge 
Samsung to Invest $1.5 Billion in Vietnam Semiconductor Testing Plant by 2027 
Marvell Stock Rises After Record Q1 FY2027 Earnings Fueled by AI Demand 
Wall Street Climbs as Micron Leads Chip Stock Rally Amid Iran Peace Hopes 
SQM Q1 Profit More Than Doubles as Lithium Prices Surge 
Australia Inflation Cools in April as Fuel Prices Ease, But Core CPI Remains Sticky 
South Korea Central Bank Holds Interest Rates Steady Amid Inflation Concerns 
SpaceX Starship V3 Test Flight Boosts IPO Momentum Ahead of Historic Market Debut 
Elon Musk Explores Possible Tesla-SpaceX Merger Amid Growing AI Investments 
Meta AI Push Could Add $26 Billion in Revenue by 2027, Wolfe Research Says 
Macquarie Names Five Taiwan AI Stocks Set to Benefit From Data Center Growth in 2026 
BOJ Governor Ueda Warns Oil Price Shock Could Trigger Persistent Inflation 
European EV Sales Surge in April 2026 as Tesla and Chinese Automakers Gain Ground 
EU Antitrust Probe Could Lead to Massive Google Fine Under DMA Rules 
SpaceX Delays Starship V3 Launch Ahead of Potential Record IPO 
Samsung Union Dispute Escalates Over Semiconductor Bonus Vote 
Celltrion, a South Korean pharmaceutical company, revealed on Thursday, Aug. 12, that it has received emergency approval from the government of Brazil for its COVID-19 antibody treatment.
According to The Korea Herald, Celltrion shared that the Health Regulatory Agency of the said country granted emergency use authorization (EUA) for its Regkirona or CT-P59, which is a COVID-19 treatment. It was said that the agency made the decision based on the results of the drug’s clinical tests for all three phases.
Celltrion added that the Brazilian health agency also looked into their preclinical studies that show the efficacy of the treatment against COVID-19 variants. Once it is made available in Brazil, Regkirona will be utilized for the treatment of adult patients who are at higher risk from COVID-19 and experiencing both mild and severe symptoms.
Korea Biomedical Review reported that adults aged 65 or older with mild and moderate symptoms would also be treated with Celltrion’s antibody drug. With the high number of daily coronavirus cases in Brazil today, Celltrion said it will deliver Rekirona to the country as fast as it could to help treat the patients.
In the COVID-19 world statistics on Worldometer, Brazil has more than 20 million cases of coronavirus infection and more than 560,000 deaths. With the spread of the more contagious Delta variant, the country is recording daily cases of around 10,000 to 30,000.
“Based on the safety and efficacy proven through large-scale global clinical data of Regkirona, the company has obtained emergency use approval from the Brazilian health authorities,” a Celltrion official stated. “We will do our best to contribute to preventing the spread of Covid-19 by supplying Regkirona early to Brazil, where the number of confirmed cases has recently rapidly increased to 30,000 a day due to the spread of the Delta variant.”
Celltrion declared that its Rekirona antibody treatment drug could reduce the risk of the coronavirus infection from progressing to a severe stage. The pharmaceutical firm further said that it could lessen the recovery time as well. Meanwhile, with the Brazilian EUA, Celltrion is planning to submit an application for similar authorization in the U.S.
